Kuroda S.,Okayama University of Science |
Kuroda S.,University of Houston |
Urata Y.,Oncolys BioPharma Inc. |
Fujiwara T.,Okayama University of Science
Acta Medica Okayama | Year: 2012
Radiotherapy plays a central part in cancer treatment, and use of radiosensitizing agents can greatly enhance this modality. Although studies have shown that several chemotherapeutic agents have the potential to increase the radiosensitivity of tumor cells, investigators have also studied a number of molecularly targeted agents as radiosensitizers in clinical trials based on reasonably promising pre-clinical data. Recent intense research into the DNA damage-signaling pathway revealed that ataxia-telangiectasia mutated (ATM) and the Mrell-Rad50-NBSl (MRN) complex play central roles in DNA repair and cell cycle checkpoints and that these molecules are promising targets for radiosensitization. Researchers recently developed three ATM inhibitors (KU-55933, CGK733, and CP466722) and an MRN complex inhibitor (mirin) and showed that they have great potential as radiosensitizers of tumors in preclinical studies. Additionally, we showed that a telomerase-dependent oncolytic adenovirus that we developed (OBP-301 [telomelysin]) produces profound radiosensitizing effects by inhibiting the MRN complex via the adenoviral ElB55kDa protein. A recent Phase I trial in the United States determined that telomelysin was safe and well tolerated in humans, and this agent is about to be tested in combination with radiotherapy in a clinical trial based on intriguing preclinical data demonstrating that telomelysin and ionizing radiation can potentiate each other. In this review, we highlight the great potential of ATM and MRN complex inhibitors, including telomelysin, as radiosensitizing agents.
News Article | November 25, 2016
This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects. Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteosarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteosarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Osteosarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Osteosarcoma Overview 10 Therapeutics Development 11 Pipeline Products for Osteosarcoma - Overview 11 Pipeline Products for Osteosarcoma - Comparative Analysis 12 Osteosarcoma - Therapeutics under Development by Companies 13 Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 15 Osteosarcoma - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Osteosarcoma - Products under Development by Companies 18 Osteosarcoma - Products under Investigation by Universities/Institutes 20 Osteosarcoma - Companies Involved in Therapeutics Development 21 Advaxis, Inc. 21 Amgen Inc. 22 AVEO Pharmaceuticals, Inc. 23 Bayer AG 24 Bellicum Pharmaceuticals, Inc. 25 Celldex Therapeutics, Inc. 26 CytRx Corporation 27 Eleison Pharmaceuticals, Inc. 28 Exelixis, Inc. 29 Isofol Medical AB 30 Merck & Co., Inc. 31 Merrimack Pharmaceuticals, Inc. 32 Neusentis 33 Novartis AG 34 Oncolys BioPharma Inc. 35 …Continued For more information, please visit http://www.wiseguyreports.com
Kagoshima University and Oncolys BioPharma Inc. | Date: 2012-12-12
This invention provides a therapeutic agent for hepatitis C comprising, as an active ingredient, a compound having anti-HCV activity useful in treatment of hepatitis C. The therapeutic agent for hepatitis C comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
Oncolys Biopharma Inc. | Date: 2010-09-30
The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome.
Oncolys BioPharma Inc. | Date: 2014-01-25
To provide means for treating and preventing a wide variety of cancers and tumors, including cancer in which there is PI3K/Akt pathway activation or p53 deactivation, or tumors for which chemotherapy, radiation therapy, hormone therapy, and other such conventional treatment methods have low effectiveness, different molecularly targeted drugs such as OBP-801 and PI3K inhibitorpreferably LY294002, BKM120, GDC-0941, BEZ235, BYL719, or CH5132799are used in combination. This makes it possible to simultaneously obtain a plurality of different marked pharmaceutical benefits which are synergistic, not being obtainable through use of a formulation with either of the respective molecularly targeted drugs alone, such as caspase pathway activation, enhanced expression of Bim, increased accumulation of intracellular reactive oxygen species, and suppressed expression of survivin and XIAP protein, and makes it possible to provide new and clinically effective tumor treatment/prevention strategies.
Oncolys BioPharma Inc. | Date: 2011-04-20
A reagent for cancer cell detection or cancer diagnosis comprises a recombinant adenovirus where a replication cassette comprising a promoter from human telomerase, an adenovirus E1A gene, an IRES sequence and an adenovirus E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the adenovirus genome.
Oncolys BioPharma Inc. | Date: 2010-09-15
Disclosed is a method for mass-producing 4-ethynyl d4T (4-ethynyl-2,3-didehydro-3-deoxythymidine) by a simpler process at low cost. Specifically disclosed is a method for producing 4-ethynyl d4T, which is characterized by comprising a step for introducing a triple bond-containing group into a furfuryl alcohol derivative or a levoglucosenone, by reacting the furfuryl alcohol derivative or levoglucosenone with a certain compound, and a step for reacting a compound represented by the formula (III), which is obtained by the aforementioned step, with thymine.
Sakai and Oncolys BioPharma Inc. | Date: 2015-12-02
To provide means for treating and preventing a wide variety of cancers and tumors, including cancer in which there is PI3K/Akt pathway activation or p53 deactivation, or tumors for which chemotherapy, radiation therapy, hormone therapy, and other such conventional treatment methods have low effectiveness, different molecularly targeted drugs such as OBP-801 and PI3K inhibitor-preferably LY294002, BKM120, GDC-0941, BEZ235, BYL719, or CH5132799-are used in combination. This makes it possible to simultaneously obtain a plurality of different marked pharmaceutical benefits which are synergistic, not being obtainable through use of a formulation with either of the respective molecularly targeted drugs alone, such as caspase pathway activation, enhanced expression of Bim, increased accumulation of intracellular reactive oxygen species, and suppressed expression of +survivin and XIAP protein, and makes it possible to provide new and clinically effective tumor treatment/prevention strategies in the form of effective therapeutic agents and prophylactic agents capable of application to a wide variety of tumors.
Kansai Technology Licensing Organization Co. and Oncolys Biopharma Inc. | Date: 2010-07-19
By using a virus having a gene sequence comprising a telomerase promoter and an E1 gene (preferably a sequence comprising E1A gene, IRES sequence and E1B gene) or by using an anticancer agent comprising the virus, the virus replicates in cancer cells to thereby produce an efficient anticancer effect.
Oncolys BioPharma Inc. | Date: 2015-10-29
Pharmaceutical preparations for use in chemotherapy, for the treatment of cancer.